TY - JOUR
T1 - Characterization of the Pall Celeris system as a point-of-care device for therapeutic angiogenesis
AU - Spaltro, Gabriella
AU - Straino, Stefania
AU - Gambini, Elisa
AU - Bassetti, Beatrice
AU - Persico, Luca
AU - Zoli, Stefano
AU - Zanobini, Marco
AU - Capogrossi, Maurizio C.
AU - Spirito, Rita
AU - Quarti, Cinzia
AU - Pompilio, Giulio
PY - 2015
Y1 - 2015
N2 - Background aims: The Pall Celeris system is a filtration-based point-of-care device designed to obtain a high concentrate of peripheral blood total nucleated cells (PB-TNCs). We have characterized the Pall Celeris-derived TNCs for their in vitro and in vivo angiogenic potency. Methods: PB-TNCs isolated from healthy donors were characterized through the use of flow cytometry and functional assays, aiming to assess migratory capacity, ability to form capillary-like structures, endothelial trans-differentiation and paracrine factor secretion. In a hind limb ischemia mouse model, we evaluated perfusion immediately and 7 days after surgery, along with capillary, arteriole and regenerative fiber density and local bio-distribution. Results: Human PB-TNCs isolated by use of the Pall Celeris filtration system were shown to secrete a panel of angiogenic factors and migrate in response to vascular endothelial growth factor and stromal-derived factor-1 stimuli. Moreover, after injection in a mouse model of hind limb ischemia, PB-TNCs induced neovascularization by increasing capillary, arteriole and regenerative fiber numbers, with human cells detected in murine tissue up to 7 days after ischemia. Conclusions: The Pall Celeris system may represent a novel, effective and reliable point-of-care device to obtain a PB-derived cell product with adequate potency for therapeutic angiogenesis.
AB - Background aims: The Pall Celeris system is a filtration-based point-of-care device designed to obtain a high concentrate of peripheral blood total nucleated cells (PB-TNCs). We have characterized the Pall Celeris-derived TNCs for their in vitro and in vivo angiogenic potency. Methods: PB-TNCs isolated from healthy donors were characterized through the use of flow cytometry and functional assays, aiming to assess migratory capacity, ability to form capillary-like structures, endothelial trans-differentiation and paracrine factor secretion. In a hind limb ischemia mouse model, we evaluated perfusion immediately and 7 days after surgery, along with capillary, arteriole and regenerative fiber density and local bio-distribution. Results: Human PB-TNCs isolated by use of the Pall Celeris filtration system were shown to secrete a panel of angiogenic factors and migrate in response to vascular endothelial growth factor and stromal-derived factor-1 stimuli. Moreover, after injection in a mouse model of hind limb ischemia, PB-TNCs induced neovascularization by increasing capillary, arteriole and regenerative fiber numbers, with human cells detected in murine tissue up to 7 days after ischemia. Conclusions: The Pall Celeris system may represent a novel, effective and reliable point-of-care device to obtain a PB-derived cell product with adequate potency for therapeutic angiogenesis.
KW - Angiogenesis
KW - Hind limb ischemia
KW - Peripheral blood cells
KW - Point-of-care
UR - http://www.scopus.com/inward/record.url?scp=84946486866&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84946486866&partnerID=8YFLogxK
U2 - 10.1016/j.jcyt.2015.04.006
DO - 10.1016/j.jcyt.2015.04.006
M3 - Article
C2 - 26038175
AN - SCOPUS:84946486866
VL - 17
SP - 1302
EP - 1313
JO - Cytotherapy
JF - Cytotherapy
SN - 1465-3249
IS - 9
ER -